Literature DB >> 21390494

Characterizing the impact of 25 years of DCIS treatment.

Elissa M Ozanne1, Yiwey Shieh, James Barnes, Colleen Bouzan, E Shelley Hwang, Laura J Esserman.   

Abstract

The significant increase in the detection and treatment of ductal carcinoma in situ (DCIS) since the introduction of screening mammography has not been accompanied by the anticipated reduction in invasive breast cancer (IBC) incidence. The prevalence of DCIS requires a reexamination of the population level effects of detecting and treating DCIS. To further our understanding of the possible impact of DCIS diagnosis and treatment on IBC incidence in the U.S., we simulated breast cancer incidence over 25 years under various assumptions regarding the baseline incidence of IBC and the progression of DCIS to IBC. The simulations demonstrate a tradeoff between the expected increased incidence of IBC absent any DCIS detection and treatment and the rate of progression of DCIS to IBC. Our analyses indicate that a high progression of DCIS to IBC implies a significant increase in incidence of IBC over what is observed had we not detected and treated DCIS. Conversely, if we assume that there would not have been a significant increase over and above the observed incidence evident in SEER, then our model indicates that the rate of DCIS progression to clinically significant IBC is low. Given the tradeoff illustrated by our model, we must reevaluate the assumption that DCIS is a short-term obligate precursor of invasive cancer and instead focus on further exploration of the true natural history of DCIS.

Entities:  

Mesh:

Year:  2011        PMID: 21390494     DOI: 10.1007/s10549-011-1430-5

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  33 in total

1.  Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.

Authors:  Amy Trentham-Dietz; Mehmet Ali Ergun; Oguzhan Alagoz; Natasha K Stout; Ronald E Gangnon; John M Hampton; Kim Dittus; Ted A James; Pamela M Vacek; Sally D Herschorn; Elizabeth S Burnside; Anna N A Tosteson; Donald L Weaver; Brian L Sprague
Journal:  Breast Cancer Res Treat       Date:  2017-11-28       Impact factor: 4.872

2.  Can Occult Invasive Disease in Ductal Carcinoma In Situ Be Predicted Using Computer-extracted Mammographic Features?

Authors:  Bibo Shi; Lars J Grimm; Maciej A Mazurowski; Jay A Baker; Jeffrey R Marks; Lorraine M King; Carlo C Maley; E Shelley Hwang; Joseph Y Lo
Journal:  Acad Radiol       Date:  2017-05-11       Impact factor: 3.173

3.  Incidence of Ductal Carcinoma In Situ in the United States, 2000-2014.

Authors:  Marc D Ryser; Laura H Hendrix; Mathias Worni; Yiling Liu; Terry Hyslop; E Shelley Hwang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-06-11       Impact factor: 4.254

Review 4.  Ductal carcinoma in situ: a brief review of treatment variation and impacts on patients and society.

Authors:  Christine Vatovec; Mujde Z Erten; Jane Kolodinsky; Phil Brown; Marie Wood; Ted James; Brian L Sprague
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2014       Impact factor: 1.807

5.  Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ.

Authors:  Laura C Collins; Ninah Achacoso; Reina Haque; Larissa Nekhlyudov; Suzanne W Fletcher; Charles P Quesenberry; Stuart J Schnitt; Laurel A Habel
Journal:  Breast Cancer Res Treat       Date:  2013-04-27       Impact factor: 4.872

6.  Modeling Ductal Carcinoma In Situ (DCIS): An Overview of CISNET Model Approaches.

Authors:  Nicolien T van Ravesteyn; Jeroen J van den Broek; Xiaoxue Li; Harald Weedon-Fekjær; Clyde B Schechter; Oguzhan Alagoz; Xuelin Huang; Donald L Weaver; Elizabeth S Burnside; Rinaa S Punglia; Harry J de Koning; Sandra J Lee
Journal:  Med Decis Making       Date:  2018-04       Impact factor: 2.583

7.  Variation in detection of ductal carcinoma in situ during screening mammography: a survey within the International Cancer Screening Network.

Authors:  Elsebeth Lynge; Antonio Ponti; Ted James; Ondřej Májek; My von Euler-Chelpin; Ahti Anttila; Patricia Fitzpatrick; Alfonso Frigerio; Masaaki Kawai; Astrid Scharpantgen; Mireille Broeders; Solveig Hofvind; Carmen Vidal; Maria Ederra; Dolores Salas; Jean-Luc Bulliard; Mariano Tomatis; Karla Kerlikowske; Stephen Taplin
Journal:  Eur J Cancer       Date:  2013-09-13       Impact factor: 9.162

8.  Addressing overdiagnosis and overtreatment in cancer: a prescription for change.

Authors:  Laura J Esserman; Ian M Thompson; Brian Reid; Peter Nelson; David F Ransohoff; H Gilbert Welch; Shelley Hwang; Donald A Berry; Kenneth W Kinzler; William C Black; Mina Bissell; Howard Parnes; Sudhir Srivastava
Journal:  Lancet Oncol       Date:  2014-05       Impact factor: 41.316

Review 9.  Breast cancer screening: the questions answered.

Authors:  Philippe Autier; Laura J Esserman; Chris I Flowers; Nehmat Houssami
Journal:  Nat Rev Clin Oncol       Date:  2012-08-14       Impact factor: 66.675

10.  Chronological Trends of Breast Ductal Carcinoma In Situ: Clinical, Radiologic, and Pathologic Perspectives.

Authors:  Si Eun Lee; Ha Yan Kim; Jung Hyun Yoon; Eun-Kyung Kim; Jee Ye Kim; Min Jung Kim; Ga Ram Kim; Youngjean Vivian Park; Hee Jung Moon
Journal:  Ann Surg Oncol       Date:  2021-07-01       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.